Targeting the DNA Damage Response for Anti-Cancer Therapy
Over the past decade a complex role for DNA damage response (DDR) in tumorigenesis has emerged. A proficient DDR has been shown to be a primary cause for cellular resistance to the very many DNA damaging drugs, and IR, that are widely used as standard-of-care across multiple cancer types. It has als...
Συγγραφή απο Οργανισμό/Αρχή: | |
---|---|
Άλλοι συγγραφείς: | , |
Μορφή: | Ηλεκτρονική πηγή Ηλ. βιβλίο |
Γλώσσα: | English |
Έκδοση: |
Cham :
Springer International Publishing : Imprint: Humana,
2018.
|
Έκδοση: | 1st ed. 2018. |
Σειρά: | Cancer Drug Discovery and Development,
|
Θέματα: | |
Διαθέσιμο Online: | Full Text via HEAL-Link |
Πίνακας περιεχομένων:
- 1. Targeting DNA repair in anti-cancer treatments
- 2. The DNA damage response: roles in cancer etiology and treatment
- 3. Control of DNA Replication by ATR
- 4. Targeting ATR for cancer therapy: Profile & expectations for ATR inhibitors
- 5. Targeting ATR for cancer therapy: ATR-targeted drug candidates
- 6. ATM: its recruitment, activation, signalling and contribution to tumour suppression
- 7. Pre-clinical profile and expectations for pharmacological ATM inhibition
- 8. Targeting ATM for cancer therapy: Prospects for drugging ATM
- 9. Targeting Chk1 for cancer therapy: rationale, progress and prospects
- 10. Preclinical profiles and contexts for CHK1 and CHK2 inhibitors
- 11. Clinical development of CHK1 inhibitors
- 12. Established and emerging roles of the DNA-dependent protein kinase catalytic subunit (DNA-PKcs)
- 13. Targeting DNA-PK as a therapeutic approach in oncology
- 14. Dbait: a new concept of DNA repair pathways inhibitor from bench to bedside
- 15. Alternative Non Homologous End-joining: Mechanisms and Targeting Strategies in Cancer.